{"id":"coagadex","rwe":[],"tags":[],"trials":[],"_chembl":{"chemblId":"CHEMBL4297951","moleculeType":"Unknown"},"aliases":["Factor X"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"ad20e6ff-98bc-47e6-aa00-7fb441edd2b0","title":"COAGADEX (COAGULATION FACTOR X HUMAN) KIT [BIO PRODUCTS LABORATORY LTD]"},"ecosystem":[],"_scrapedAt":"2026-03-28T02:31:35.531Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06963216","phase":"PHASE3","title":"A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis","status":"RECRUITING","sponsor":"Kedrion S.p.A.","startDate":"2026-02","conditions":"Acquired Factor X Deficiency","enrollment":15},{"nctId":"NCT04563520","phase":"PHASE3","title":"SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis","status":"RECRUITING","sponsor":"Emory University","startDate":"2026-03","conditions":"Hemophilia A","enrollment":5},{"nctId":"NCT06929260","phase":"PHASE1","title":"A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2025-05-21","conditions":"Advanced Solid Tumours","enrollment":1},{"nctId":"NCT05568888","phase":"PHASE3","title":"Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )","status":"TERMINATED","sponsor":"CSL Behring","startDate":"2023-03-28","conditions":"Traumatic Injury","enrollment":1366},{"nctId":"NCT04244981","phase":"PHASE4","title":"Efficacy of Prothrombin Complex Concentrate Reducing Perioperative Blood Loss in Cardiac Surgery","status":"RECRUITING","sponsor":"SHI Jia","startDate":"2023-10-25","conditions":"Cardiac Surgical Procedures","enrollment":820},{"nctId":"NCT06517563","phase":"PHASE1","title":"Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin","status":"ACTIVE_NOT_RECRUITING","sponsor":"VarmX B.V.","startDate":"2024-08-14","conditions":"Coagulation Disorder","enrollment":16},{"nctId":"NCT04023019","phase":"","title":"Treatment of Hemophilia A Patients With FVIII Inhibitors","status":"RECRUITING","sponsor":"Emory University","startDate":"2020-03-17","conditions":"Hemophilia A","enrollment":120},{"nctId":"NCT06372483","phase":"PHASE1","title":"Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant","status":"ACTIVE_NOT_RECRUITING","sponsor":"VarmX B.V.","startDate":"2024-02-21","conditions":"Coagulation Disorder","enrollment":40},{"nctId":"NCT05226442","phase":"PHASE2, PHASE3","title":"Safety and Feasibility of Argatroban As Anticoagulant in Adults with ECMO","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2021-12-01","conditions":"Extracorporeal Membrane Oxygenation Complication, Anticoagulants and Bleeding Disorders","enrollment":40},{"nctId":"NCT04539301","phase":"","title":"Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2021-04-01","conditions":"Anticoagulation, Venous Thromboembolism, Atrial Fibrillation","enrollment":2100},{"nctId":"NCT03921294","phase":"PHASE4","title":"HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor","status":"TERMINATED","sponsor":"Indiana Hemophilia &Thrombosis Center, Inc.","startDate":"2019-05-15","conditions":"Haemophilic Pseudotumour","enrollment":1},{"nctId":"NCT04567511","phase":"PHASE4","title":"Hemlibra in Mild Hemophilia A","status":"RECRUITING","sponsor":"Indiana Hemophilia &Thrombosis Center, Inc.","startDate":"2022-07-25","conditions":"Factor VIII Deficiency, Congenital","enrollment":20},{"nctId":"NCT05152420","phase":"PHASE1","title":"Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects","status":"COMPLETED","sponsor":"VarmX B.V.","startDate":"2021-10-29","conditions":"Coagulation Disorder","enrollment":105},{"nctId":"NCT04233073","phase":"PHASE2","title":"Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2021-06-27","conditions":"Surgery","enrollment":10},{"nctId":"NCT02740335","phase":"PHASE3","title":"Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.","status":"COMPLETED","sponsor":"Octapharma","startDate":"2017-06-08","conditions":"Significant Bleeding Risk","enrollment":208},{"nctId":"NCT04569279","phase":"PHASE3","title":"Rivaroxaban vs. Warfarin in CVT Treatment","status":"COMPLETED","sponsor":"Damascus University","startDate":"2017-09-01","conditions":"Cerebral Vein Thrombosis","enrollment":71},{"nctId":"NCT03161626","phase":"","title":"Registry Study of COAGADEX® Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery","status":"COMPLETED","sponsor":"Bio Products Laboratory","startDate":"2018-02-27","conditions":"Factor 10 Deficiency","enrollment":3},{"nctId":"NCT05012501","phase":"","title":"Analysis of Neutrophil Extracellular Traps in Hypercoagulability and Portal Vein Thrombosis in Liver Cirrhosis Patients","status":"COMPLETED","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2020-09-01","conditions":"Neutrophil Extracellular Trap Formation, Portal Vein Thrombosis, Liver Cirrhosis","enrollment":79},{"nctId":"NCT02319460","phase":"","title":"An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2014-04-24","conditions":"Hemorrhage","enrollment":2238},{"nctId":"NCT03347591","phase":"","title":"Rare Bleeding Disorders in the Netherlands","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2017-11-07","conditions":"Rare Bleeding Disorders","enrollment":300},{"nctId":"NCT04372173","phase":"","title":"An Evaluation of Clotting Factor Activity Before and After Total Hip Arthroplasty","status":"COMPLETED","sponsor":"Military Institute od Medicine National Research Institute","startDate":"2018-02-01","conditions":"Arthroplasty, Replacement, Coagulation Factors","enrollment":30},{"nctId":"NCT00970619","phase":"PHASE3","title":"DUTCH CAVA-trial: CAtheter Versus Anticoagulation Alone for Acute Primary (Ilio)Femoral DVT.","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2010-05","conditions":"Acute Thrombosis of Deep Veins of Proximal Lower Extremity","enrollment":184},{"nctId":"NCT03270865","phase":"NA","title":"Usability and Ergonomic Evaluation of Self-Positioning System for Retinal Imaging","status":"COMPLETED","sponsor":"Notal Vision Ltd.","startDate":"2017-09-30","conditions":"AMD Population - Intermediate or Advanced AMD, DR Population- With or Without Diabetic Macular Edema","enrollment":16},{"nctId":"NCT03287999","phase":"","title":"Inter Individual Variability in Initiation Pathway Activation and Regulation and Phenotypic Heterogeneity in Patients With Haemophilia A and B","status":"UNKNOWN","sponsor":"Royal Free Hospital NHS Foundation Trust","startDate":"2017-09-19","conditions":"Haemophilia","enrollment":250},{"nctId":"NCT02047565","phase":"PHASE1","title":"A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2013-10","conditions":"Bleeding","enrollment":110},{"nctId":"NCT01086852","phase":"PHASE3","title":"Safety & Efficacy of BPL's High Purity FACTOR X in Treatment of Factor X Deficient Subjects Undergoing Surgery","status":"TERMINATED","sponsor":"Bio Products Laboratory","startDate":"2011-03","conditions":"Factor X Deficiency","enrollment":4},{"nctId":"NCT01721681","phase":"PHASE3","title":"A Study to Investigate Bio Product Laboratory Ltd (BPL's) Factor X in the Prophylaxis of Bleeding in Children <12 Years","status":"COMPLETED","sponsor":"Bio Products Laboratory","startDate":"2015-04","conditions":"Factor X Deficiency","enrollment":9},{"nctId":"NCT02914353","phase":"PHASE1","title":"Study to Evaluate Safety, PK and PD of Single and Multiple Ascending Doses of EP-7041 in Healthy Subjects","status":"COMPLETED","sponsor":"eXIthera Pharmaceuticals","startDate":"2016-07","conditions":"Arthroplasty, Replacement, Knee","enrollment":80},{"nctId":"NCT02099318","phase":"NA","title":"Surgical Theater's Surgery Rehearsal Platform","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2013-02","conditions":"Cerebral Aneurysm Unruptured, Cerebral Aneurysm Ruptured","enrollment":40},{"nctId":"NCT01656330","phase":"PHASE1","title":"A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-07","conditions":"Healthy","enrollment":35},{"nctId":"NCT02463591","phase":"PHASE2","title":"Reversal of Dabigatran With Prothrombin Complex Concentrate","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2015-01","conditions":"Drug Action Reversal","enrollment":12},{"nctId":"NCT01687491","phase":"PHASE4","title":"Comparison of Anti-Xa Activity of ENOXA ® Versus LOVENOX ® in Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Les Laboratoires des Médicaments Stériles","startDate":"2012-07","conditions":"Acute Coronary Syndrome, Factor X","enrollment":179},{"nctId":"NCT02074358","phase":"PHASE1","title":"A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-02","conditions":"Anticoagulation","enrollment":43},{"nctId":"NCT01660061","phase":"","title":"Monitoring Anticoagulant Therapy in Antiphospholipid Syndrome","status":"COMPLETED","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2011-07","conditions":"Antiphospholipid Syndrome","enrollment":150},{"nctId":"NCT00930176","phase":"PHASE3","title":"A Study Investigating Treatment Factor X in People With Factor X Deficiency","status":"COMPLETED","sponsor":"Bio Products Laboratory","startDate":"2010-01","conditions":"Factor X Deficiency","enrollment":16},{"nctId":"NCT01352143","phase":"","title":"Thrombin Generation in Neonatal Plasma After Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Emory University","startDate":"2011-03","conditions":"Cardiopulmonary Bypass","enrollment":24},{"nctId":"NCT00986635","phase":"","title":"Effect of Rivaroxaban on Coagulation Parameters- an ex Vivo Study","status":"COMPLETED","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2009-09","conditions":"Differences in Laboratory Coagulation Parameters","enrollment":100},{"nctId":"NCT00458666","phase":"","title":"Coagulation Parameters During Pregnancy in Amniotic Fluid","status":"UNKNOWN","sponsor":"Rambam Health Care Campus","startDate":"2006-06","conditions":"Pregnancy","enrollment":170},{"nctId":"NCT00257179","phase":"","title":"The Serum Tissue Factor Level in Lung Cancer Patients as a Prognostic Factor","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2005-06","conditions":"Lung Cancer","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":5,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Coagadex","genericName":"Coagadex","companyName":"Bio Products Laboratory","companyId":"bio-products-laboratory","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}